<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab3">
 <label>Table 3</label>
 <caption>
  <p>Experimental treatments for SARS-CoV-2 infection</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="left">Drug</th>
    <th align="left">Results so far</th>
    <th align="left">Potential NMD-relevant side effects</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left">Chloroquine (CQ)/Hydroxychloroquine (HCQ)</td>
    <td align="left">
     <p>Open label studies of HCQ + azithromycin found an increased rate of viral load reduction or disappearance and clinical amelioration in most patients [
      <xref ref-type="bibr" rid="CR60">60</xref>, 
      <xref ref-type="bibr" rid="CR61">61</xref>]
     </p>
     <p>Randomized study of high vs. low dose of CQ failed to detect benefits (small sample size?) but higher CQ dosage not recommended because of potential cardiac toxicity [
      <xref ref-type="bibr" rid="CR62">62</xref>]
     </p>
    </td>
    <td align="left">
     <p>QTc interval prolongation, favoring fatal arrhythmias, such as ventricular tachycardia and torsade de pointes, especially when combined with other QTc-prolonging drugs [
      <xref ref-type="bibr" rid="CR63">63</xref>]
     </p>
     <p>CK elevation common</p>
     <p>Long-term use associated with risk of developing toxic neuromyopathy [
      <xref ref-type="bibr" rid="CR64">64</xref>] and with onset or worsening of MG [
      <xref ref-type="bibr" rid="CR65">65</xref>]
     </p>
    </td>
   </tr>
   <tr>
    <td align="left">Lopinavir/Ritonavir (LPV/RTV)</td>
    <td align="left">Randomized trial found it did not improve outcome compared to SSC alone</td>
    <td align="left">
     <p>QTc interval prolongation, favoring fatal arrhythmias, such as ventricular tachycardia and torsade de pointes, especially when combined with other QTc-prolonging drugs</p>
     <p>Risk of toxic myopathy in association with statins</p>
    </td>
   </tr>
   <tr>
    <td align="left">Remdesivir</td>
    <td align="left">61 patients with severe COVID-19 were treated with remdesivir on a compassionate use basis: 68% of patients showed improvement, 15% worsened [
     <xref ref-type="bibr" rid="CR66">66</xref>]
    </td>
    <td align="left">
     <p>Myalgias in healthy controls [
      <xref ref-type="bibr" rid="CR67">67</xref>]
     </p>
     <p>Elevation in liver enzymes [
      <xref ref-type="bibr" rid="CR66">66</xref>]
     </p>
    </td>
   </tr>
   <tr>
    <td align="left">Azithromycin</td>
    <td align="left">Open label studies of HCQ + azithromycin found increased rate of viral load reduction or disappearance and clinical amelioration in most patients [
     <xref ref-type="bibr" rid="CR60">60</xref>, 
     <xref ref-type="bibr" rid="CR61">61</xref>]
    </td>
    <td align="left">
     <p>QTc interval prolongation</p>
     <p>Risk of worsening MG</p>
    </td>
   </tr>
   <tr>
    <td align="left">Tocilizumab (TCZ)</td>
    <td align="left">Decrease in CRP levels in five patients receiving two or more TCZ administrations</td>
    <td align="left">Elevation in liver enzymes</td>
   </tr>
   <tr>
    <td align="left">Eculizumab (ECZ)</td>
    <td align="left">Clinical amelioration and drop in inflammatory markers in 4 critically ill patients treated with ECZ [
     <xref ref-type="bibr" rid="CR68">68</xref>]
    </td>
    <td align="left">
     <p>Myalgias and arthralgias</p>
     <p>Elevation in liver enzymes</p>
    </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>
   <italic>CK </italic>creatine kinase,
   <italic> CQ </italic>chloroquine,
   <italic> CRP </italic>C-reactive protein, 
   <italic>ECZ </italic>eculizumab,
   <italic> HCQ </italic>hydroxychloroquine,
   <italic> LPV/RTV </italic>lopinavir/ritonavir,
   <italic> MG </italic>myasthenia gravis, 
   <italic>SSC</italic> standard supportive care,
   <italic> TCZ </italic>tociluzumab
  </p>
 </table-wrap-foot>
</table-wrap>
